Up next

Autoplay

ISAR REACT- 5: Ticagrelor versus prasugrel in patients with ACS - ESC Congress 2019

1 Views • 08/26/25
Share
Side Effects
Side Effects
Subscribers
0

Stefanie Schuepke presenter of the ISAR REACT 5 trial explains the background and findings of this major trial. ISAR REACT 5 is the first large-sized trial which compared prasugrel and ticagrelor in ACS. The previously presented PRAGUE 18 trial was smaller and ultimately inconclusive. Hence, for the first time, we have evidence comparing the two drugs in a large scale randomized setting.

View a written analysis of this trial here:
https://www.pcronline.com/News..../Whats-new-on-PCRonl
Participate in a cardio poll regarding the results of ISAR REACT-5 :
https://www.pcronline.com/News..../Cardio-Poll/ISAR-RE
#ESCCongress

Show more
0 Comments sort Sort By

Up next

Autoplay